PHARMACY

Daschle to take point on health overhaul plan

BY Jim Frederick

WASHINGTON The standard-bearer for President-elect Barack Obama’s ambitious plan to reform the beleaguered U.S. healthcare system will be a soft-spoken consensus-builder who once held one of the most powerful posts in Congress.

Obama’s choice for secretary of Health and Human Services, former Senate Majority Leader Tom Daschle, may prove an astute choice to champion the newly elected president’s health reform package. A 26-year veteran of Congress, Daschle was an early supporter of Obama who urged him to run for president and helped line up support in Congress for the freshman senator from Illinois, reportedly damaging a long-term relationship with both Bill and Hillary Clinton in the process.

Daschle, who represented South Dakota, has served as a policy advisor for a well-connected Washington law firm since he was voted out of office in 2004. But he has firm opinions about fixing the healthcare system, even publishing a book early this year titled, “Critical: What We Can Do About the Health Care Crisis.”

In that tome, Daschle argues for creation of an independent federal health board, along the lines of the Federal Reserve Board, to craft policy and set a unified standard of care, free of politics. He’s also a vocal proponent of the rapid conversion to health information technology and health coverage for the nation’s more than 45 million uninsured.

Among those who have praised Daschle’s ideas is the president-elect himself. “The American healthcare system is in crisis, and workable solutions have been blocked for years by deeply entrenched ideological divisions,” Obama wrote earlier this year. “Sen. Daschle brings fresh thinking to this problem, and his Federal Reserve for Health concept holds great promise for bridging this intellectual chasm and, at long last, giving this nation the health care it deserves.” 

As of press time in late November, Daschle had reportedly accepted the post of HHS secretary, but other posts within the Department of Health and Human Services, including Obama’s picks to head the Centers for Medicare and Medicaid Services and the Food and Drug Administration, were yet to be announced. Some pharmaceutical industry groups were urging the president-elect to tap Dr. Janet Woodcock, a longtime FDA official now in charge of the agency’s Center for Drug Evaluation and Research, for the post, saying she would hit the ground running and follow through on efforts at the FDA to modernize and speed up its drug review and approval practices.

The selection of Daschle drew praise from independent pharmacy leaders stung by what they perceive as an era of neglect under the Bush White House. “The National Community Pharmacists Association would like to congratulate Tom Daschle on being selected to be secretary of HHS in the Obama-Biden administration next year,” said NCPA executive vice president and chief executive officer Bruce Roberts. “During his time in the Senate, Mr. Daschle embraced common-sense policies that allowed our more than 23,000 members to operate on a level playing field in providing patients with their healthcare needs.” 

As the top health official in the land, Daschle inherits a weighty task: to take point on his boss’s plan to overhaul the massive U.S. healthcare system and expand coverage to more Americans.

That has been a long-stated goal of Barack Obama, and it has gained new urgency amid a crisis in health care and the economy. Also spurring calls for reform in recent weeks has been Sen. Edward Kennedy, who returned to Capitol Hill last month during a lull in his treatment for brain cancer to unveil an ambitious plan to push legislation in early 2009 that would extend universal health coverage.

Among other influential Democratic lawmakers advancing health reform plans in recent weeks are Senate Finance Committee chairman Max Baucus of Montana (see story in the Chain Pharmacy section of this issue).

Knowing that no major healthcare reform plan can succeed without the support of both parties, Obama has made a point of reaching out to Republican leaders in the House and Senate to help craft policy.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Drug inspectors receive Aleong National Patient Safety Award

BY Alaric DeArment

FT. LAUDERDALE, Fla. Two drug inspectors in Florida have received the first annual Stephanie F. Aleong, J.D., National Patient Safety Award from Nova Southeastern University.

NSU announced that Brand Institute president and chief executive officer James Dettore and NSU dean Andres Malave presented the award last month to Gene Odin and Cesar Arias, two state drug inspectors who worked on a task force to investigate pharmaceutical drug abuse with Aleong, a prosecutor and NSU law professor who died in October.

The work of Aleong and the two inspectors resulted in counterfeiters of drugs for cancer, cholesterol, HIV and organ transplants being imprisoned, the university said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Study results show Lipitor helps reduce rate of heart-health emergencies

BY Alaric DeArment

NEW YORK Results of an observational study indicate that patients taking Pfizer’s Lipitor (atorvastatin calcium) had a 13 percent reduction in the relative risk of heart-related emergencies compared to Merck’s Zocor (simvastatin), drug maker Pfizer said Wednesday.

The study, published in the December issue of Mayo Clinic Proceedings, was based on the managed care claims of patients between 18 and 64. The patients had recently begun using the drugs, had not used statins before and did not have evident cardiovascular disease. The average doses in the study were 29 mg of Zocor and 17 mg of Lipitor. It did not find any significant difference among patients with the secondary endpoints of stroke, revascularization surgery or peripheral vascular disease.

“Observational data such as this, which reflect the use of medicines in real-world clinical practice rather than in a controlled trial setting, mayhelp healthcare providers and managed care companies improve clinical outcomes for patients,” Emory University medicine professor and director of the health promotion and disease prevention office at Grady Health Systems Terry Jacobson said in a statement.

The study analyzed claims for statin prescriptions filed between January 2003 and December 2005 by patients having their first inpatient or emergency room admission for heart disease, heart attack, chest pain, certain heart surgeries, peripheral vascular disease, swelling of the aorta, stroke and transient ischemic attack.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?